Exelixis
EXEL
$36.48
Share price
2.50%
Change (1 day)
59.51%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Earnings for Exelixis (EXEL)
Earnings in 2024 (TTM): $0.68 Billion USD
According to Exelixis's latest financial reports the company's current earnings are $2.16 Billion USD. , an increase over its 2023 earnings that were of $0.25 Billion USD. The earnings displayed on this page is the company's Pretax Income.
Earnings history for Exelixis from 2000 to 2024
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2024  | $0.68 B | 164.69% |
| 2023 | $0.25 B | 9.89% |
| 2022 | $0.23 B | -20.33% |
| 2021 | $0.29 B | 124.82% |
| 2020 | $0.13 B | -67.14% |
| 2019 | $0.39 B | -11.94% |
| 2018 | $0.45 B | 185.09% |
| 2017 | $0.15 B | -325.82% |
| 2016 | -$70.23 Million | -58.12% |
| 2015 | -$0.17 Billion | -37.61% |
| 2014 | -$0.27 Billion | 9.75% |
| 2013 | -$0.25 Billion | 65.96% |
| 2012 | -$0.15 Billion | -291.63% |
| 2011 | $76.99 M | -195.59% |
| 2010 | -$80.55 Million | -42.17% |
| 2009 | -$0.14 Billion | -18.98% |
| 2008 | -$0.18 Billion | -6.99% |
| 2007 | -$0.19 Billion | 46.3% |
| 2006 | -$0.13 Billion | 33.25% |
| 2005 | -$94.81 Million | -30.92% |
| 2004 | -$0.14 Billion | 44.29% |
| 2003 | -$95.12 Million | 12.86% |
| 2002 | -$84.29 Million | 22.79% |
| 2001 | -$68.65 Million | 60.14% |
| 2000 | -$42.87 Million |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 | $4.39 B | 544.70% | 🇬🇧 UK |
 | $7.94 B | 1,065.14% | 🇫🇷 France |
 | $21.20 B | 3,011.17% | 🇺🇸 USA |
 | -$8.38 Billion | -1,329.24% | 🇺🇸 USA |
 | $4.60 B | 576.16% | 🇺🇸 USA |
 | $17.44 B | 2,458.83% | 🇺🇸 USA |
 | $11.11 B | 1,530.33% | 🇺🇸 USA |
 | -$42.78 Million | -106.28% | 🇺🇸 USA |
 | -$29.04 Million | -104.26% | 🇺🇸 USA |